vimarsana.com

Latest Breaking News On - Chronic disease patients - Page 3 : vimarsana.com

PhableCare Raises INR 187 Cr (USD 25 M) in Series B Funding

Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round Funds will be used to strengthen full-stack and value-driven chronic care ecosystem, accelerate market expansion, customer acquisition, building new revenue streams Increases PhableCares valuation by 6x Bengaluru headquartered, PhableCare, Indias largest chronic disease management company, has raised Series B funding of INR 187 crores USD 25 Million within one year of raising Series A.

My father might have lived : families of Hong Kong s Covid-19 victims urge hospitals to prioritise most vulnerable patients

Polypill Products Market: Developments, Growth and 2019-2027 Forecast Research Study – KSU

tmrMay 14, 2021 Polypill Products Market: Introduction According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is projected to expand at a CAGR of ~2% from 2019 to 2027. Polypill is a fixed dose drug combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases. Polypill improves patient compliance, thereby increasing the adoption of these products. This is likely to boost the growth of the global polypill products market. Moreover, ease of dosage understanding for elderly patients and increase in usage of polypill products are the major advantages offered by polypill products over other formulations. Combination therapy is more effective than a single substance with an acceptable safety profile. North America dominated the global polypill products market in 2018 and the trend is anticipated to continue duri

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.